Hannah Castro

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. pmc Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children
    Linda Harrison
    Medical Research Council Clinical Trials Unit, Aviation House, 125 Kingsway, London, WC2B 6NH, UK
    AIDS Behav 17:193-202. 2013
  2. ncbi request reprint Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
    H Green
    MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
    AIDS 21:947-55. 2007
  3. pmc Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study
    David Dolling
    UK HIV Drug Resistance Database, MRC Clinical Trials Unit, London WC2B 6NH, UK
    BMJ 345:e5253. 2012
  4. doi request reprint The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
  5. pmc Persistence of HIV-1 transmitted drug resistance mutations
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Infect Dis 208:1459-63. 2013
  6. pmc Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, UK
    BMC Med Res Methodol 12:30. 2012
  7. doi request reprint Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK
    Julie Fox
    Department of HIV, Guys and St Thomas NHS Trust Kings College London, St Thomas Hospital, London, UK
    AIDS 24:2397-401. 2010
  8. doi request reprint HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
    Daniella N Chilton
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 15:985-91. 2010
  9. pmc First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
    Abdel Babiker
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet Infect Dis 11:273-83. 2011
  10. pmc Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Tim R Cressey
    Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 46:1601-8. 2008

Detail Information

Publications12

  1. pmc Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children
    Linda Harrison
    Medical Research Council Clinical Trials Unit, Aviation House, 125 Kingsway, London, WC2B 6NH, UK
    AIDS Behav 17:193-202. 2013
    ..004). The majority of families indicated they were happy to have further PTIs (carer: 23/36, 64 %; children: 8/13, 62 %), however many reported more clinic visits during PTI were a problem (carer: 15/36, 42 %; children: 6/12, 50 %)...
  2. ncbi request reprint Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
    H Green
    MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
    AIDS 21:947-55. 2007
    ..To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial...
  3. pmc Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study
    David Dolling
    UK HIV Drug Resistance Database, MRC Clinical Trials Unit, London WC2B 6NH, UK
    BMJ 345:e5253. 2012
    ..To evaluate whether the prevalence of HIV-1 transmitted drug resistance has continued to decline in infections probably acquired within the United Kingdom...
  4. doi request reprint The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
    ..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus...
  5. pmc Persistence of HIV-1 transmitted drug resistance mutations
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Infect Dis 208:1459-63. 2013
    ..Our estimates are important for informing HIV transmission models. ..
  6. pmc Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, UK
    BMC Med Res Methodol 12:30. 2012
    ..However estimates of the prevalence of TDR will also be distorted if some ART-experienced patients are misclassified as ART-naïve...
  7. doi request reprint Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK
    Julie Fox
    Department of HIV, Guys and St Thomas NHS Trust Kings College London, St Thomas Hospital, London, UK
    AIDS 24:2397-401. 2010
    ..To describe the frequency and risk factors of non-B HIV-1 subtypes in men who have sex with men (MSM) in the UK...
  8. doi request reprint HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
    Daniella N Chilton
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 15:985-91. 2010
    ..We examined the characteristics of HIV-1 drug resistance in antiretroviral treatment (ART)-naive individuals migrating to the UK...
  9. pmc First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
    Abdel Babiker
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet Infect Dis 11:273-83. 2011
    ..We assess the long-term outcome of protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line ART and viral load switch criteria in children...
  10. pmc Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Tim R Cressey
    Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 46:1601-8. 2008
    ....
  11. ncbi request reprint Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome
    J P Aboulker
    AIDS 18:237-45. 2004
    ..To assess the feasibility and impact of highly active antiretroviral therapy (HAART) started in vertically HIV-1-infected infants less than 3 months of age...